AbbVie Gets Accelerated Public Reimbursement Approval Of Epkinly In Nine Canadian Provinces
Monday announced that nine provinces have approved accelerated public coverage of Epkinly, a treatment for adult ...
Nine Provinces Approve Accelerated Public Reimbursement of Diffuse Large B-Cell Lymphoma Treatment Under New Early Access Process
AbbVie (NYSE: ABBV), today announced that nine (9) provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...
AbbVie Falters Despite Progress in Lymphoma Treatment
AbbVie (NYSE: ABBV) today announced that nine provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...
Narus Financial Partners LLC Has $476,000 Stock Position in AbbVie Inc. (NYSE:ABBV)
Narus Financial Partners LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 8.4% in the 3rd quarter, ...
BMO Capital Markets Boosts AbbVie (NYSE:ABBV) Price Target to $220.00
AbbVie (NYSE:ABBV – Free Report) had its target price upped by BMO Capital Markets from $214.00 to $220.00 in a research note ...
pharmaphorum2d
CD20 market heats up as FDA OKs AbbVie, Genmab bispecific
Micrograph of a diffuse large B cell lymphoma, AbbVie and partner Genmab have FDA approval for the lead drug in their $3.9 billion cancer partnership, with bispecific antibody Epkinly now cleared ...
12 Analysts Have This To Say About Genmab
Genmab GMAB over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes ...
pharmaphorum2d
After ph3 win, Roche eyes earlier use of Columvi in DLBCL
In that indication, the drug competes with AbbVie and Genmab’s rival CD20xCD3 bispecific Epkinly (epcoritamab), so moving it into the first relapse setting could hand Roche an advantage.